MC
CERO

Meteora Capital’s CERo Therapeutics CERO Stock Holding History

Meteora Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-121
Closed -$2.68M – 302
2023
Q4 		$2.68M Buy
121
+36
+42% +$785K 0.45% 64
2023
Q3 		$1.84M Buy
85
+9
+12% +$195K 0.31% 89
2023
Q2 		$1.66M Sell
76
-27
-26% -$585K 0.31% 103
2023
Q1 		$2.19M Buy
103
+19
+23% +$401K 0.26% 107
2022
Q4 		$1.73M Buy
84
+2
+2% +$40.8K 0.37% 68
2022
Q3 		$1.66M Buy
+82
New +$1.65M 0.42% 69

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PA
Pineridge Advisors St. Charles, Missouri $350M AUM 6.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meteora Capital's CERO Position: Q1 2024 in Review

Meteora Capital sold out of CERo Therapeutics (CERO) in Q1 2024, closing a stake of 121 shares — an estimated $2.68M sold.

Meteora Capital first reported a position in CERO in Q3 2022 and held it in 6 quarters. The position peaked at $2.68M in Q4 2023. 7 funds tracked by Wall St. Rank hold CERO as of Q1 2024.

  • Meteora Capital reported no remaining CERo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Meteora Capital sold 121 CERo Therapeutics shares in Q1 2024, an estimated $2.68M.
  • Meteora Capital first reported a position in CERo Therapeutics in Q3 2022 and held it in 6 quarters.
  • Meteora Capital's CERo Therapeutics position peaked at $2.68M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2024.

Based on Meteora Capital's 13F filing for Q1 2024, filed 14 May 2024.